Get the Stockscreener App
199.33
0.86%
-1.73
After Hours:
199.64
0.31
+0.16%
Jazz Pharmaceuticals Plc stock is traded at $199.33, with a volume of 658.35K.
It is down -0.86% in the last 24 hours and up +11.64% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$201.06
Open:
$202
24h Volume:
658.35K
Relative Volume:
0.69
Market Cap:
$12.27B
Revenue:
$4.27B
Net Income/Loss:
$-356.15M
P/E Ratio:
-33.39
EPS:
-5.9702
Net Cash Flow:
$1.19B
1W Performance:
+1.74%
1M Performance:
+11.64%
6M Performance:
+46.78%
1Y Performance:
+93.69%
1-Day Range:
$198.94
$202.57
1-Week Range:
$192.32
$202.57
52-Week Range:
$97.50
$202.57
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
199.33 | 12.38B | 4.27B | -356.15M | 1.19B | -5.9702 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Feb-27-26 | Initiated | Barclays | Overweight |
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting - Sleep Review
Jazz Pharmaceuticals enters exclusive licensing deal with Saniona - MSN
Whats the RSI of Jazz Pharmaceuticals plc stockMarket Trend Review & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Bond Watch: Will CNH Industrial NV outperform its industry peers2026 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn
Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally? - simplywall.st
Why Jazz Pharmaceuticals Stock’s EPS is Set to 3x in 2026 - TIKR.com
Does New Epidiolex Behavioral Data at AAN 2026 Reframe Jazz Pharmaceuticals’ (JAZZ) Neuroscience Strategy? - simplywall.st
Is Jazz Pharmaceuticals plc exposed to political risk2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
Jazz Pharmaceuticals PLC Stock Intrinsic Values - GuruFocus
Jazz Pharmaceuticals (JAZZ) Receives Outperform Rating with New Price Target - GuruFocus
Is Jazz Pharmaceuticals (JAZZ) one of the best cheap biotech stocks to buy now? - MSN
Jazz Pharmaceuticals stock hits all-time high at 198.01 USD By Investing.com - Investing.com Australia
Patterns Watch: Is Jazz Pharmaceuticals plc exposed to political riskMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
Raymond James initiates Jazz Pharmaceuticals stock coverage with outperform rating - Investing.com UK
Jazz Pharmaceuticals stock hits all-time high at 198.01 USD - Investing.com
Asparaginase Market Key Companies AnalysisServier - openPR.com
Jazz Pharmaceuticals Presents Research at AAN Annual Meeting on Rare Neurological Disorders - Intellectia AI
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting - PR Newswire
Jazz Pharmaceuticals PLC Stock Warning Signs | BSP:J2AZ34 - GuruFocus
Who's Buying or Selling Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Today? - GuruFocus
Jazz Pharmaceuticals PLC Stock Operating Data - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Earnings Transcripts - GuruFocus
Jazz Pharmaceuticals PLC Stock Historical Valuations | BSP:J2AZ34 - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Competitors 2026 - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Price & 30 Year Financial Data - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Dividend - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock News, Headlines & Updates - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Valuation: Modestly Overvalued - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) DCF Valuation - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Price, Trades & News - GuruFocus
Decliners Report: Is Jazz Pharmaceuticals plc subject to activist investor interest2026 Winners & Losers & Safe Entry Point Identification - baoquankhu1.vn
Jazz Pharmaceuticals PLC R (J7Z.HM) Q2 FY2025 earnings call transcript - Yahoo Finance
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart.com
Epilepsy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharma, SK Biopharma - Barchart.com
Jazz projects $4.25B–$4.50B 2026 revenue while advancing rare disease and oncology launches - MSN
Autistic Disorder Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Bioscienc - Barchart.com
Jazz Pharmaceuticals plc (JAZZ) reports $1.2 billion Q4 revenue, beats $1.17B estimate - MSN
Rate Cut: Whats the RSI of Jazz Pharmaceuticals plc stockWeekly Stock Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Capricorn Fund Managers Ltd Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why is Jazz (JAZZ) down 3.9% since last earnings report? - MSN
Jazz Pharmaceuticals PLC (J7Z.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
JAZZ Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Perpetual Ltd Lowers Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (J7Z.HM) stock major holders - Yahoo Finance Singapore
Jazz Pharmaceuticals PLC (J7Z.HM) stock price, news, quote and history - Yahoo Finance Singapore
Insider Sell: Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - uk.finance.yahoo.com
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 6,000 Shares of Stock - MarketBeat
Director at Jazz Pharmaceuticals (JAZZ) sells 6,000 company shares - Stock Titan
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):